Evidence map›Paper›PMID 33012205›Full record

ArticleHypertension (Dallas, Tex. : 1979)2020

Impaired Hedgehog-Gli1 Pathway Activity Underlies the Vascular Phenotype of Polycystic Kidney Disease.

Federico Franchi, Karen M Peterson, Katherine Quandt, David Domnick, Timothy L Kline, Michaela Olthoff, Mojtaba Parvizi, Ezequiel J Tolosa, Vicente E Torres, Peter C Harris and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Nile Tilapia (International journal of molecular sciences · 2024
    Article
  2. Mechanisms of endothelial flow sensing.Nature cardiovascular research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Federico FranchiFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Karen M PetersonFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Katherine QuandtFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
David DomnickFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Timothy L KlineDepartment of Radiology (T.L.K.), Mayo Clinic, Rochester, MN.
Michaela OlthoffFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Mojtaba ParviziFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Ezequiel J TolosaSchulze Center for Novel Therapeutic, Division of Oncology Research (E.J.T., M.E.F.-Z.), Mayo Clinic, Rochester, MN.
Vicente E TorresDivision of Nephrology and Hypertension (V.E.T., P.C.H.), Mayo Clinic, Rochester, MN.
Peter C HarrisDivision of Nephrology and Hypertension (V.E.T., P.C.H.), Mayo Clinic, Rochester, MN.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutic, Division of Oncology Research (E.J.T., M.E.F.-Z.), Mayo Clinic, Rochester, MN.
Martin G Rodriguez-PorcelFrom the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN.
Mayo Clinic · USMayo Clinic Health System · USMayo Clinic in Arizona · US

Funding

Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 2010 to 2019
$11.8M
Transgenic and Knockout Models of ADPKDR01DK059597 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris · 2002 to 2026
$9.5M
CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
Imaging mitochondrial function of progenitor cells transplanted to the ischemic myocardiumR01HL119795 · NHLBI · MAYO CLINIC ROCHESTER · PI RODRIGUEZ-PORCEL, MARTIN · 2016 to 2020
$3.1M
Mayo Clinic Summer Undergraduate Research in Nephrology & UrologyR25DK101405 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL F. ROMERO · 2014 to 2026
$1.6M
Non-invasive imaging of progenitor cell fate in the ischemic myocardiumR56HL113371 · NHLBI · MAYO CLINIC ROCHESTER · PI RODRIGUEZ-PORCEL, MARTIN · 2013 to 2013
$533k
NHLBI NIH HHS R01 HL119795NHLBI NIH HHS R56 HL113371NHLBI NIH HHS T32 HL007111NIDDK NIH HHS P30 DK090728NIDDK NIH HHS R01 DK059597NIDDK NIH HHS R25 DK101405
6 · The paper itself

Abstract

Polycystic kidney disease (PKD) has been linked to abnormal structure/function of ciliary proteins, leading to renal dysfunction. Recently, attention has been focused in the significant vascular abnormalities associated with PKD, but the mechanisms underlying this phenomenon remain elusive. Here, we seek to define the molecular events regulating the angiogenic imbalance observed in PKD. Using micro computed tomography (n=7) and protein expression analysis (n=5), we assessed the vascular density and the angiogenic profile of noncystic organs in a well-established PKD rat model (Polycystic Kidney-PCK rat). Heart and lungs of PCK rats have reduced vascular density and decreased expression of angiogenic factors compared with wild type. Similarly, PCK-vascular smooth muscle cells (VSMCs; n=4) exhibited lower levels of vascular markers. Then, using small interfering RNA (n=4), we determined the role of the ciliary protein fibrocystin in wild type-VSMCs, a critical component/regulator of vascular structure and function. Reduction of fibrocystin in wild type-VSMCs (n=4) led to an abnormal angiogenic potential similar to that observed in PCK-VSMCs. Furthermore, we investigated the involvement of the hedgehog signaling, a pathway closely linked to the primary cilium and associated with vascular development, in PKD. Mechanistically, we demonstrated that impairment of the hedgehog signaling mediates, in part, this abnormal angiogenic phenotype. Lastly, overexpression of Gli1 in PCK-VSMCs (n=4) restored the expression levels of proangiogenic molecules. Our data support a critical role of fibrocystin in the abnormal vascular phenotype of PKD and indicate that a dysregulation of hedgehog may be responsible, at least in part, for these vascular deficiencies.

Indexed as

Disease Models, AnimalSignal TransductionAnimalsBlood VesselsCells, CulturedCiliaHedgehog ProteinsHumansMuscle, Smooth, VascularMyocytes, Smooth MusclePhenotypePolycystic Kidney DiseasesRats, Sprague-DawleyX-Ray MicrotomographyZinc Finger Protein GLI1Hedgehog ProteinsZinc Finger Protein GLI1cell signalingciliahedgehog pathwaykidneyvascular smooth muscle

Identifiers

PMID33012205
PMCPMC7666088
OpenAlexW3089926509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.